Advancing Blood-Based Biomarkers in Alzheimer’s: From Preclinical Detection to Population Diversity at AD/PD 2025  

Today’s presentations at AD/PD 2025 underscored just how far we’ve come, and how far we still have to go, in leveraging blood-based biomarkers for Alzheimer’s disease.  

Two standout sessions highlighted both technological breakthroughs and the critical importance of inclusive research. In the first session, “Plasma SNAP25 Has Diagnostic and Prognostic Potential in Pre-Clinical Alzheimer’s Disease”, researchers demonstrated that SNAP25, a synaptic integrity marker previously thought to be CSF-restricted, can be reliably measured in plasma using Simoa®. The results were striking; plasma SNAP25 showed an AUC of 80% for predicting disease progression; rising to 92% when combined with p-tau217.  

These findings point to a future where high-performance, non-invasive diagnostics are within reach- powered by the Quanterix’s technology.  

Equally important was a second session, “Hyperglycemia, Diabetes Status, and ATN Blood Biomarkers in Hispanic/Latino Populations”, which explored how comorbidities and ethnicity influence biomarker expression. Using Simoa to measure NfL, GFAP, Aβ40, Aβ42, and p-tau181, researchers found that p-tau181, NfL, and Aβ were all sensitive to diabetes status, with p-tau181 emerging as a particularly strong marker in men. This data underscores the urgent need to expand biomarker validation efforts across diverse populations and real-world conditions, including metabolic disorders like diabetes.  

Together, these studies reflect a powerful shift: from theoretical biomarker promise to practical, personalized application. Quanterix is proud to support this movement with the tools that make these discoveries possible; because understanding disease begins with measuring it precisely, and inclusively.  

We also had three great in-booth presentations today including: Mathias Sauer from the University of Gothenburg on the development and validation of a novel simoa assay for NPTX2 in Alzheimer’s Disease and Down syndrome; Suvi Rovio from the University of Turku on gut microbiota shaping human cognitive function phenotype – Introduction to the MicroCOGNI study; and Elise Thijssen from Neurogen Biomarking on a scalable ecosystem supporting early detection of Alzheimer’s Disease. 

We’re on to the final day of #ADPD25, come visit us at booth #22! 

Read the key takeaways from Day 3 here.